# Roberto Bolli

## List of Publications by Year in Descending Order



| | | | |
|---|---|---|---|
| 312 papers | 21,573 citations | 80 h-index | 141 g-index |
| 347 ext. papers | 23,532 ext. citations | 9.6 avg, IF | 6.85 L-index |

| # | Paper | IF | Citations |
|---|---|---|---|
| 312 | Transient Cell Cycle Induction in Cardiomyocytes to Treat Subacute Ischemic Heart Failure.. *Circulation*, **2022**, | 16.7 | 1 |
| 311 | Clinical trials of cell therapy for heart failure: recent results warrant continued research. *Current Opinion in Cardiology*, **2022**, 37, 193-200 | 2.1 | 0 |
| 310 | Effect of intravenous cell therapy in rats with old myocardial infarction. *Molecular and Cellular Biochemistry*, **2021**, 1 | 4.2 | 1 |
| 309 | Basic and Translational Research in Cardiac Repair and Regeneration: JACC State-of-the-Art Review. *Journal of the American College of Cardiology*, **2021**, 78, 2092-2105 | 15.1 | 3 |
| 308 | Comparison of Repeated Doses of C-kit-Positive Cardiac Cells versus a Single Equivalent Combined Dose in a Murine Model of Chronic Ischemic Cardiomyopathy. *International Journal of Molecular Sciences*, **2021**, 22, | 6.3 | 1 |
| 307 | Reparative cell therapy for the heart: critical internal appraisal of the field in response to recent controversies. *ESC Heart Failure*, **2021**, 8, 2306-2309 | 3.7 | 2 |
| 306 | Cell Therapy in Patients with Heart Failure: A Comprehensive Review and Emerging Concepts. *Cardiovascular Research*, **2021**, | 9.9 | 8 |
| 305 | A Phase II study of autologous mesenchymal stromal cells and c-kit positive cardiac cells, alone or in combination, in patients with ischaemic heart failure: the CCTRN CONCERT-HF trial. *European Journal of Heart Failure*, **2021**, 23, 661-674 | 12.3 | 26 |
| 304 | Insights into therapeutic products, preclinical research models, and clinical trials in cardiac regenerative and reparative medicine: where are we now and the way ahead. Current opinion paper of the ESC Working Group on Cardiovascular Regenerative and Reparative Medicine. *Cardiovascular Research*, **2021**, 117, 1428-1433 | 9.9 | 7 |
| 303 | Comparison of One and Three Intraventricular Injections of Cardiac Progenitor Cells in a Murine Model of Chronic Ischemic Cardiomyopathy. *Stem Cell Reviews and Reports*, **2021**, 17, 604-615 | 7.3 | 6 |
| 302 | Echocardiography-guided percutaneous left ventricular intracavitary injection as a cell delivery approach in infarcted mice. *Molecular and Cellular Biochemistry*, **2021**, 476, 2135-2148 | 4.2 | 3 |
| 301 | After the storm: an objective appraisal of the efficacy of c-kit+ cardiac progenitor cells in preclinical models of heart disease. *Canadian Journal of Physiology and Pharmacology*, **2021**, 99, 129-139 | 2.4 | 7 |
| 300 | Single dose of synthetic microRNA-199a or microRNA-149 mimic does not improve cardiac function in a murine model of myocardial infarction. *Molecular and Cellular Biochemistry*, **2021**, 476, 4093-4106 | 4.2 | 1 |
| 299 | Cell therapy for nonischemic dilated cardiomyopathy: A systematic review and meta-analysis of randomized controlled trials. *Stem Cells Translational Medicine*, **2021**, 10, 1394-1405 | 6.9 | 2 |
| 298 | Recommendations for Nomenclature and Definition Of Cell Products Intended for Human Cardiovascular Use. *Cardiovascular Research*, **2021**, | 9.9 | 2 |
| 297 | Peripheral Blood Biomarkers Associated With Improved Functional Outcome in Patients With Chronic Left Ventricular Dysfunction: A Biorepository Evaluation of the FOCUS-CCTRN Trial. *Frontiers in Cardiovascular Medicine*, **2021**, 8, 698088 | 5.4 | 0 |
| 296 | Cell cycle induction in human cardiomyocytes is dependent on biosynthetic pathway activation. *Redox Biology*, **2021**, 46, 102094 | 11.3 | 3 |

| | | | |
|---|---|---|---|
| 295 | Exercise-induced late preconditioning in mice is triggered by eNOS-dependent generation of nitric oxide and activation of PKC□and is mediated by increased iNOS activity. *International Journal of Cardiology*, **2021**, 340, 68-78 | 3.2 | 6 |
| 294 | Effects of Heme Oxygenase-1 on c-Kit-Positive Cardiac Cells.. *International Journal of Molecular Sciences*, **2021**, 22, | 6.3 | 1 |
| 293 | Meta-analysis of short- and long-term efficacy of mononuclear cell transplantation in patients with myocardial infarction. *American Heart Journal*, **2020**, 220, 155-175 | 4.9 | 4 |
| 292 | A realistic appraisal of the use of embryonic stem cell-based therapies for cardiac repair. *European Heart Journal*, **2020**, 41, 2397-2404 | 9.5 | 15 |
| 291 | Heart slice culture system reliably demonstrates clinical drug-related cardiotoxicity. *Toxicology and Applied Pharmacology*, **2020**, 406, 115213 | 4.6 | 5 |
| 290 | Allogeneic Mesenchymal Cell Therapy in Anthracycline-Induced Cardiomyopathy Heart Failure Patients: The CCTRN SENECA Trial. *JACC: CardioOncology*, **2020**, 2, 581-595 | 3.8 | 12 |
| 289 | Administration of cardiac mesenchymal cells modulates innate immunity in the acute phase of myocardial infarction in mice. *Scientific Reports*, **2020**, 10, 14754 | 4.9 | 3 |
| 288 | Molecular and Cellular Mechanisms Associated with Effects of Molecular Hydrogen in Cardiovascular and Central Nervous Systems. *Antioxidants*, **2020**, 9, | 7.1 | 7 |
| 287 | Slicing and Culturing Pig Hearts under Physiological Conditions. *Journal of Visualized Experiments*, **2020**, | 1.6 | 5 |
| 286 | Ten Years at the Helm of Circulation Research. *Circulation Research*, **2019**, 124, 1707-1717 | 15.7 | 1 |
| 285 | Pro-Angiogenic Actions of CMC-Derived Extracellular Vesicles Rely on Selective Packaging of Angiopoietin 1 and 2, but Not FGF-2 and VEGF. *Stem Cell Reviews and Reports*, **2019**, 15, 530-542 | 6.4 | 11 |
| 284 | William Harvey and the Discovery of the Circulation of the Blood. *Circulation Research*, **2019**, 124, 1428-1429 | 15.7 | 1 |
| 283 | William Harvey and the Discovery of the Circulation of the Blood. *Circulation Research*, **2019**, 124, 1169-1171 | 15.7 | 3 |
| 282 | Human Embryonic Stem Cell-Derived Cardiomyocytes. *Circulation Research*, **2019**, 124, 1157-1159 | 15.7 | 4 |
| 281 | William Harvey and the Discovery of the Circulation of the Blood. *Circulation Research*, **2019**, 124, 1300-1302 | 15.7 | 5 |
| 280 | Potential Strategies for Clinical Translation of Repeated Cell Therapy. *Circulation Research*, **2019**, 124, 690-692 | 15.7 | 9 |
| 279 | Perspectives on Directions and Priorities for Future Preclinical Studies in Regenerative Medicine. *Circulation Research*, **2019**, 124, 938-951 | 15.7 | 20 |
| 278 | Physiological Biomimetic Culture System for Pig and Human Heart Slices. *Circulation Research*, **2019**, 125, 628-642 | 15.7 | 29 |

| | | | |
|---|---|---|---|
| 277 | Inducible cardiac-specific overexpression of cyclooxygenase-2 (COX-2) confers resistance to ischemia/reperfusion injury. *Basic Research in Cardiology*, **2019**, 114, 32 | 11.8 | 9 |
| 276 | Ectopic Cardiogenic Transcription Factor Expression Augments the Anti-fibrogenic Activity of Administered Cardiac Mesenchymal Stromal Cells in a Model of Chronic Ischemic Cardiomyopathy. *FASEB Journal*, **2019**, 33, lb476 | 0.9 | |
| 275 | Oxygen Administration Does Not Influence the Prognosis of Acute Myocardial Infarction: A Meta-Analysis. *American Journal of Therapeutics*, **2019**, 26, e151-e160 | 1 | 1 |
| 274 | Repeated Administrations of Cardiac Progenitor Cells Are Superior to a Single Administration of an Equivalent Cumulative Dose. *Journal of the American Heart Association*, **2018**, 7, | 6 | 29 |
| 273 | Translational Research in Cardiovascular Repair: A Call for a Paradigm Shift. *Circulation Research*, **2018**, 122, 310-318 | 15.7 | 36 |
| 272 | Rationale and Design of the CONCERT-HF Trial (Combination of Mesenchymal and c-kit Cardiac Stem Cells As Regenerative Therapy for Heart Failure). *Circulation Research*, **2018**, 122, 1703-1715 | 15.7 | 72 |
| 271 | Short and Long Noncoding RNAs Regulate the Epigenetic Status of Cells. *Antioxidants and Redox Signaling*, **2018**, 29, 832-845 | 8.4 | 12 |
| 270 | Guidelines for experimental models of myocardial ischemia and infarction. *American Journal of Physiology - Heart and Circulatory Physiology*, **2018**, 314, H812-H838 | 5.2 | 249 |
| 269 | New Paradigms in Cell Therapy: Repeated Dosing, Intravenous Delivery, Immunomodulatory Actions, and New Cell Types. *Circulation Research*, **2018**, 123, 138-158 | 15.7 | 67 |
| 268 | Clinical Studies of Cell Therapy in Cardiovascular Medicine: Recent Developments and Future Directions. *Circulation Research*, **2018**, 123, 266-287 | 15.7 | 81 |
| 267 | Rationale and Design of the SENECA (StEm cell iNjECtion in cAncer survivors) Trial. *American Heart Journal*, **2018**, 201, 54-62 | 4.9 | 15 |
| 266 | Transcription Factor STAT3 Serves as a Negative Regulator Controlling IgE Class Switching in Mice. *ImmunoHorizons*, **2018**, 2, 349-362 | 2.7 | 8 |
| 265 | Cell therapy for heart disease: current status and future directions. *Minerva Cardiology and Angiology*, **2018**, 66, 273-291 | 2.4 | 3 |
| 264 | Epigenetically modified cardiac mesenchymal stromal cells limit myocardial fibrosis and promote functional recovery in a model of chronic ischemic cardiomyopathy. *Basic Research in Cardiology*, **2018**, 114, 3 | 11.8 | 37 |
| 263 | Anthology of Images. *Circulation Research*, **2018**, 122, 5-5 | 15.7 | 1 |
| 262 | Effect of Molecular Weight on Sonoporation-Mediated Uptake in Human Cells. *Ultrasound in Medicine and Biology*, **2018**, 44, 2662-2672 | 3.5 | 10 |
| 261 | Cardiac mesenchymal cells from diabetic mice are ineffective for cell therapy-mediated myocardial repair. *Basic Research in Cardiology*, **2018**, 113, 46 | 11.8 | 36 |
| 260 | Increased Risk of Adverse Neurocognitive Outcomes With Proprotein Convertase Subtilisin-Kexin Type 9 Inhibitors. *Circulation: Cardiovascular Quality and Outcomes*, **2017**, 10, | 5.8 | 41 |

| | | | |
|---|---|---|---|
| 259 | Evaluation of Cell Therapy on Exercise Performance and Limb Perfusion in Peripheral Artery Disease: The CCTRN PACE Trial (Patients With Intermittent Claudication Injected With ALDH Bright Cells). *Circulation*, **2017**, 135, 1417-1428 | 16.7 | 29 |
| 258 | Repeated doses of cardiac mesenchymal cells are therapeutically superior to a single dose in mice with old myocardial infarction. *Basic Research in Cardiology*, **2017**, 112, 18 | 11.8 | 61 |
| 257 | Announcing the "Meet the First Author" Page. *Circulation Research*, **2017**, 120, 595 | 15.7 | 2 |
| 256 | Repeated Cell Therapy: A Paradigm Shift Whose Time Has Come. *Circulation Research*, **2017**, 120, 1072-1074 | 15.7 | 44 |
| 255 | Neurocognitive Risk With PCSK9 Inhibitors: Need for More Robust Evidence. *Journal of the American College of Cardiology*, **2017**, 69, 2468-2469 | 15.1 | 1 |
| 254 | Peripheral Blood Cytokine Levels After Acute Myocardial Infarction: IL-1 and IL-6-Related Impairment of Bone Marrow Function. *Circulation Research*, **2017**, 120, 1947-1957 | 15.7 | 27 |
| 253 | Myocardial Reparative Properties of Cardiac Mesenchymal Cells Isolated on the Basis of Adherence. *Journal of the American College of Cardiology*, **2017**, 69, 1824-1838 | 15.1 | 34 |
| 252 | Stem cells: Cell therapy for cardiac repair: what is needed to move forward?. *Nature Reviews Cardiology*, **2017**, 14, 257-258 | 14.8 | 27 |
| 251 | Transcription factor-induced activation of cardiac gene expression in human c-kit+ cardiac progenitor cells. *PLoS ONE*, **2017**, 12, e0174242 | 3.7 | 11 |
| 250 | Global position paper on cardiovascular regenerative medicine. *European Heart Journal*, **2017**, 38, 2532-2546 | 15.1 | 90 |
| 249 | Overcoming the Roadblocks to Cardiac Cell Therapy Using Tissue Engineering. *Journal of the American College of Cardiology*, **2017**, 70, 766-775 | 15.1 | 67 |
| 248 | Trainees in the Spotlight: Yet Another Addition to Our Portfolio. *Circulation Research*, **2017**, 120, 1048-1049 | 15.7 | 1 |
| 247 | Histone Deacetylase 1 Depletion Activates Human Cardiac Mesenchymal Stromal Cell Proangiogenic Paracrine Signaling Through a Mechanism Requiring Enhanced Basic Fibroblast Growth Factor Synthesis and Secretion. *Journal of the American Heart Association*, **2017**, 6, | 6 | 7 |
| 246 | Cardiomyocyte Regeneration: A Consensus Statement. *Circulation*, **2017**, 136, 680-686 | 16.7 | 287 |
| 245 | Circulating Biomarkers to Identify Responders in Cardiac Cell therapy. *Scientific Reports*, **2017**, 7, 4419 | 4.9 | 14 |
| 244 | Identification of cardiovascular risk factors associated with bone marrow cell subsets in patients with STEMI: a biorepository evaluation from the CCTRN TIME and LateTIME clinical trials. *Basic Research in Cardiology*, **2017**, 112, 3 | 11.8 | 11 |
| 243 | Therapy with c-kitPOS Cardiac Stem Cells for Ischemic Cardiomyopathy **2016**, 201-215 | | |
| 242 | Repeated Administrations of Cardiac Progenitor Cells Are Markedly More Effective Than a Single Administration: A New Paradigm in Cell Therapy. *Circulation Research*, **2016**, 119, 635-51 | 15.7 | 79 |

| | | | |
|---|---|---|---|
| 241 | The Promise and Challenge of Induced Pluripotent Stem Cells for Cardiovascular Applications. *JACC Basic To Translational Science*, **2016**, 1, 510-523 | 8.7 | 26 |
| 240 | Impact of Cell Therapy on Myocardial Perfusion and Cardiovascular Outcomes in Patients With Angina Refractory to Medical Therapy: A Systematic Review and Meta-Analysis. *Circulation Research* , **2016**, 118, 984-93 | 15.7 | 56 |
| 239 | Long-Term Outcome of Administration of c-kit(POS) Cardiac Progenitor Cells After Acute Myocardial Infarction: Transplanted Cells Do not Become Cardiomyocytes, but Structural and Functional Improvement and Proliferation of Endogenous Cells Persist for at Least One Year. *Circulation Research*, **2016**, 118, 1091-105 | 15.7 | 112 |
| 238 | Concise Review: Review and Perspective of Cell Dosage and Routes of Administration From Preclinical and Clinical Studies of Stem Cell Therapy for Heart Disease. *Stem Cells Translational Medicine*, **2016**, 5, 186-91 | 6.9 | 83 |
| 237 | A New Method to Stabilize C-Kit Expression in Reparative Cardiac Mesenchymal Cells. *Frontiers in Cell and Developmental Biology*, **2016**, 4, 78 | 5.7 | 27 |
| 236 | TNF receptor signaling inhibits cardiomyogenic differentiation of cardiac stem cells and promotes a neuroadrenergic-like fate. *American Journal of Physiology - Heart and Circulatory Physiology*, **2016**, 311, H1189-H1201 | 5.2 | 9 |
| 235 | Type 2 Diabetes Dysregulates Glucose Metabolism in Cardiac Progenitor Cells. *Journal of Biological Chemistry*, **2016**, 291, 13634-48 | 5.4 | 30 |
| 234 | STAT3 Signaling in B Cells Is Critical for Germinal Center Maintenance and Contributes to the Pathogenesis of Murine Models of Lupus. *Journal of Immunology*, **2016**, 196, 4477-86 | 5.3 | 42 |
| 233 | The Epigenetic Regulator HDAC1 Modulates Transcription of a Core Cardiogenic Program in Human Cardiac Mesenchymal Stromal Cells Through a p53-Dependent Mechanism. *Stem Cells*, **2016**, 34, 2916-2929 | 5.8 | 11 |
| 232 | Genetic Deficiency of Glutathione S-Transferase P Increases Myocardial Sensitivity to Ischemia-Reperfusion Injury. *Circulation Research*, **2015**, 117, 437-49 | 15.7 | 29 |
| 231 | "String theory" of c-kit(pos) cardiac cells: a new paradigm regarding the nature of these cells that may reconcile apparently discrepant results. *Circulation Research*, **2015**, 116, 1216-30 | 15.7 | 94 |
| 230 | Effect of the stop-flow technique on cardiac retention of c-kit positive human cardiac stem cells after intracoronary infusion in a porcine model of chronic ischemic cardiomyopathy. *Basic Research in Cardiology*, **2015**, 110, 503 | 11.8 | 9 |
| 229 | Preconditioning Human Cardiac Stem Cells with an HO-1 Inducer Exerts Beneficial Effects After Cell Transplantation in the Infarcted Murine Heart. *Stem Cells*, **2015**, 33, 3596-607 | 5.8 | 35 |
| 228 | Glutamine Regulates Cardiac Progenitor Cell Metabolism and Proliferation. *Stem Cells*, **2015**, 33, 2613-27 | 5.8 | 40 |
| 227 | C-Kit Promotes Growth and Migration of Human Cardiac Progenitor Cells via the PI3K-AKT and MEK-ERK Pathways. *PLoS ONE*, **2015**, 10, e0140798 | 3.7 | 36 |
| 226 | O-GlcNAcylation Negatively Regulates Cardiomyogenic Fate in Adult Mouse Cardiac Mesenchymal Stromal Cells. *PLoS ONE*, **2015**, 10, e0142939 | 3.7 | 4 |
| 225 | Effects of Intracoronary Infusion of Escalating Doses of Cardiac Stem Cells in Rats With Acute Myocardial Infarction. *Circulation: Heart Failure*, **2015**, 8, 757-65 | 7.6 | 30 |
| 224 | The NHLBI-sponsored Consortium for preclinicAl assESsment of cARdioprotective therapies (CAESAR): a new paradigm for rigorous, accurate, and reproducible evaluation of putative infarct-sparing interventions in mice, rabbits, and pigs. *Circulation Research*, **2015**, 116, 572-86 | 15.7 | 111 |

| | | | |
|---|---|---|---|
| 223 | Safety of intracoronary infusion of 20 million C-kit positive human cardiac stem cells in pigs. *PLoS ONE*, **2015**, 10, e0124227 | 3.7 | 17 |
| 222 | Detailed analysis of bone marrow from patients with ischemic heart disease and left ventricular dysfunction: BM CD34, CD11b, and clonogenic capacity as biomarkers for clinical outcomes. *Circulation Research*, **2014**, 115, 867-74 | 15.7 | 50 |
| 221 | Endoplasmic reticulum stress-dependent activation of ATF3 mediates the late phase of ischemic preconditioning. *Journal of Molecular and Cellular Cardiology*, **2014**, 76, 138-47 | 5.8 | 26 |
| 220 | Bone marrow mononuclear cell therapy for acute myocardial infarction: a perspective from the cardiovascular cell therapy research network. *Circulation Research*, **2014**, 114, 1564-8 | 15.7 | 35 |
| 219 | Cardiac stem cell therapy for cardiac repair. *Current Treatment Options in Cardiovascular Medicine*, **2014**, 16, 324 | 2.1 | 37 |
| 218 | Co-activation of nuclear factor-Ƀ and myocardin/serum response factor conveys the hypertrophy signal of high insulin levels in cardiac myoblasts. *Journal of Biological Chemistry*, **2014**, 289, 19585-98 | 5.4 | 19 |
| 217 | c-kit+ Cardiac stem cells alleviate post-myocardial infarction left ventricular dysfunction despite poor engraftment and negligible retention in the recipient heart. *PLoS ONE*, **2014**, 9, e96725 | 3.7 | 126 |
| 216 | Statistical Methods for Selecting Maximum Effective Dose and Evaluating Treatment Effect When Dose - Response is Monotonic. *Statistics in Biopharmaceutical Research*, **2014**, 6, 16-29 | 1.2 | 5 |
| 215 | Response to letter regarding article, "Cell therapy for heart failure: a comprehensive overview of experimental and clinical studies, current challenges, and future directions". *Circulation Research*, **2014**, 115, e33-4 | 15.7 | |
| 214 | Actions speak much louder than words: for midcareer and senior investigators, the track record of productivity should be paramount in selecting grant recipients. *Circulation Research*, **2014**, 115, 962-6 | 15.7 | 4 |
| 213 | Announcing Yet Another Article Category. *Circulation Research*, **2014**, 114, 228-229 | 15.7 | 1 |
| 212 | Sodium Nitrite Fails to Limit Myocardial Infarct Size: Results from the CAESAR Cardioprotection Consortium (LB645). *FASEB Journal*, **2014**, 28, LB645 | 0.9 | 16 |
| 211 | Administration of Sildenafil at Reperfusion Fails to Reduce Infarct Size: Results from the CAESAR Cardioprotection Consortium (LB650). *FASEB Journal*, **2014**, 28, LB650 | 0.9 | 13 |
| 210 | Vascular endothelial growth factor in heart failure. *Nature Reviews Cardiology*, **2013**, 10, 519-30 | 14.8 | 148 |
| 209 | A highly sensitive and accurate method to quantify absolute numbers of c-kit+ cardiac stem cells following transplantation in mice. *Basic Research in Cardiology*, **2013**, 108, 346 | 11.8 | 96 |
| 208 | Stem cell therapy: promising treatment in heart failure?. *Current Heart Failure Reports*, **2013**, 10, 73-80 | 2.8 | 13 |
| 207 | Assessing Autophagy **2013**, 371-377 | | |
| 206 | Echocardiography: Advanced Techniques (Tissue Doppler, Speckle Tracking, and Three-Dimensional Imaging) **2013**, 275-286 | | |

| | | | |
|---|---|---|---|
| 205 | Cell therapy for heart failure: a comprehensive overview of experimental and clinical studies, current challenges, and future directions. *Circulation Research*, **2013**, 113, 810-34 | 15.7 | 429 |
| 204 | Transverse Aortic Constriction: a Model to Study Heart Failure in Small Animals **2013**, 164-169 | | 4 |
| 203 | Protein O-GlcNAcylation is a novel cytoprotective signal in cardiac stem cells. *Stem Cells*, **2013**, 31, 765-75 | 5.8 | 47 |
| 202 | In Vivo Hemodynamics **2013**, 295-304 | | |
| 201 | Intracoronary delivery of autologous cardiac stem cells improves cardiac function in a porcine model of chronic ischemic cardiomyopathy. *Circulation*, **2013**, 128, 122-31 | 16.7 | 175 |
| 200 | Models of Pacing-Induced Heart Failure **2013**, 203-214 | | |
| 199 | Isolation and Culture of Vascular smooth Muscle Cells **2013**, 125-130 | | 2 |
| 198 | Targeting phosphatidylinositol 3-kinase-Akt through hepatocyte growth factor for cardioprotection. *Journal of Cardiovascular Medicine*, **2013**, 14, 249-53 | 1.9 | 9 |
| 197 | Isolation and Culture of Cardiac Fibroblasts **2013**, 140-145 | | |
| 196 | Isolation and Culture of Cardiac Endothelial Cells **2013**, 131-139 | | |
| 195 | Cardiac stem cells in patients with ischaemic cardiomyopathy - Authors' reply. *Lancet, The*, **2012**, 379, 891-892 | 40 | 4 |
| 194 | Carbon monoxide induces a late preconditioning-mimetic cardioprotective and antiapoptotic milieu in the myocardium. *Journal of Molecular and Cellular Cardiology*, **2012**, 52, 228-36 | 5.8 | 64 |
| 193 | Administration of cardiac stem cells in patients with ischemic cardiomyopathy: the SCIPIO trial: surgical aspects and interim analysis of myocardial function and viability by magnetic resonance. *Circulation*, **2012**, 126, S54-64 | 16.7 | 367 |
| 192 | Cardiomyocyte-restricted overexpression of extracellular superoxide dismutase increases nitric oxide bioavailability and reduces infarct size after ischemia/reperfusion. *Basic Research in Cardiology*, **2012**, 107, 305 | 11.8 | 36 |
| 191 | Genetic background, gender, age, body temperature, and arterial blood pH have a major impact on myocardial infarct size in the mouse and need to be carefully measured and/or taken into account: results of a comprehensive analysis of determinants of infarct size in 1,074 mice. *Basic Research in Cardiology*, **2012**, 107, 288 | 11.8 | 39 |
| 190 | Cardioprotection **2012**, 369-388 | | 1 |
| 189 | Cardiac stem cells in patients with ischemic cardiomyopathy: discovery, translation, and clinical investigation. *Current Atherosclerosis Reports*, **2012**, 14, 491-503 | 6 | 9 |
| 188 | Identification of inducible nitric oxide synthase in peripheral blood cells as a mediator of myocardial ischemia/reperfusion injury. *Basic Research in Cardiology*, **2012**, 107, 253 | 11.8 | 24 |

| | | | |
|---|---|---|---|
| 187 | The heme oxygenase 1 inducer (CoPP) protects human cardiac stem cells against apoptosis through activation of the extracellular signal-regulated kinase (ERK)/NRF2 signaling pathway and cytokine release. *Journal of Biological Chemistry*, **2012**, 287, 33720-32 | 5.4 | 84 |
| 186 | The COX-2/PGI2 receptor axis plays an obligatory role in mediating the cardioprotection conferred by the late phase of ischemic preconditioning. *PLoS ONE*, **2012**, 7, e41178 | 3.7 | 26 |
| 185 | Protein O-GlcNAcylation A Novel Cell Survival Signal in Cardiac Stem Cells. *FASEB Journal*, **2012**, 26, 693.1 | 0.9 | 1 |
| 184 | A murine model of inducible, cardiac-specific deletion of STAT3: its use to determine the role of STAT3 in the upregulation of cardioprotective proteins by ischemic preconditioning. *Journal of Molecular and Cellular Cardiology*, **2011**, 50, 589-97 | 5.8 | 73 |
| 183 | Cardiac stem cells in patients with ischaemic cardiomyopathy (SCIPIO): initial results of a randomised phase 1 trial. *Lancet, The*, **2011**, 378, 1847-57 | 40 | 1075 |
| 182 | Transplantation of expanded bone marrow-derived very small embryonic-like stem cells (VSEL-SCs) improves left ventricular function and remodelling after myocardial infarction. *Journal of Cellular and Molecular Medicine*, **2011**, 15, 1319-28 | 5.6 | 63 |
| 181 | Development of an NIH consortium for preclinicAl AssESsment of CARdioprotective therapies (CAESAR): a paradigm shift in studies of infarct size limitation. *Journal of Cardiovascular Pharmacology and Therapeutics*, **2011**, 16, 332-9 | 2.6 | 61 |
| 180 | Intracoronary administration of cardiac stem cells in mice: a new, improved technique for cell therapy in murine models. *Basic Research in Cardiology*, **2011**, 106, 849-64 | 11.8 | 92 |
| 179 | Hematopoietic cytokines for cardiac repair: mobilization of bone marrow cells and beyond. *Basic Research in Cardiology*, **2011**, 106, 709-33 | 11.8 | 36 |
| 178 | Gene transfer as a strategy to achieve permanent cardioprotection I: rAAV-mediated gene therapy with inducible nitric oxide synthase limits infarct size 1 year later without adverse functional consequences. *Basic Research in Cardiology*, **2011**, 106, 1355-66 | 11.8 | 19 |
| 177 | Gene transfer as a strategy to achieve permanent cardioprotection II: rAAV-mediated gene therapy with heme oxygenase-1 limits infarct size 1 year later without adverse functional consequences. *Basic Research in Cardiology*, **2011**, 106, 1367-77 | 11.8 | 27 |
| 176 | New horizons in cardioprotection: recommendations from the 2010 National Heart, Lung, and Blood Institute Workshop. *Circulation*, **2011**, 124, 1172-9 | 16.7 | 175 |
| 175 | Atorvastatin therapy during the peri-infarct period attenuates left ventricular dysfunction and remodeling after myocardial infarction. *PLoS ONE*, **2011**, 6, e25320 | 3.7 | 19 |
| 174 | Human cardiac stem cells isolated from atrial appendages stably express c-kit. *PLoS ONE*, **2011**, 6, e27719 | 3.7 | 73 |
| 173 | Protein O-GlcNAcylation Exerts Mitogenic Effects in Cardiac Progenitor Cells. *FASEB Journal*, **2011**, 25, 1043.16 | 0.9 | |
| 172 | Protein O-GlcNAcylation Promotes Post-hypoxic Survival of Cardiac Progenitor Cells. *FASEB Journal* , **2011**, 25, 861.12 | 0.9 | |
| 171 | Intracoronary administration of cardiac progenitor cells alleviates left ventricular dysfunction in rats with a 30-day-old infarction. *Circulation*, **2010**, 121, 293-305 | 16.7 | 304 |
| 170 | Cardiac progenitor cells and bone marrow-derived very small embryonic-like stem cells for cardiac repair after myocardial infarction. *Circulation Journal*, **2010**, 74, 390-404 | 2.9 | 52 |

| | | | |
|---|---|---|---|
| 169 | The cornucopia of "pleiotropic" actions of statins: myogenesis as a new mechanism for statin-induced benefits?. *Circulation Research*, **2009**, 104, 144-6 | 15.7 | 8 |
| 168 | Gene transfer of inducible nitric oxide synthase affords cardioprotection by upregulating heme oxygenase-1 via a nuclear factor-{kappa}B-dependent pathway. *Circulation*, **2009**, 120, 1222-30 | 16.7 | 47 |
| 167 | The beneficial effects of postinfarct cytokine combination therapy are sustained during long-term follow-up. *Journal of Molecular and Cellular Cardiology*, **2009**, 47, 528-35 | 5.8 | 11 |
| 166 | Granulocyte colony-stimulating factor therapy for cardiac repair after acute myocardial infarction: a systematic review and meta-analysis of randomized controlled trials. *American Heart Journal*, **2008**, 156, 216-226.e9 | 4.9 | 117 |
| 165 | Endothelial nitric oxide synthase is not necessary for the early phase of ischemic preconditioning in the mouse. *Journal of Molecular and Cellular Cardiology*, **2008**, 44, 496-501 | 5.8 | 22 |
| 164 | Bone marrow-derived pluripotent very small embryonic-like stem cells (VSELs) are mobilized after acute myocardial infarction. *Journal of Molecular and Cellular Cardiology*, **2008**, 44, 865-73 | 5.8 | 65 |
| 163 | Acrolein consumption exacerbates myocardial ischemic injury and blocks nitric oxide-induced PKCepsilon signaling and cardioprotection. *Journal of Molecular and Cellular Cardiology*, **2008**, 44, 1016-22 | 5.8 | 77 |
| 162 | Cardiac stem cells and myocardial disease. *Journal of Molecular and Cellular Cardiology*, **2008**, 45, 505-13 | 5.8 | 87 |
| 161 | The role of TNF-alpha receptors p55 and p75 in acute myocardial ischemia/reperfusion injury and late preconditioning. *Journal of Molecular and Cellular Cardiology*, **2008**, 45, 735-41 | 5.8 | 36 |
| 160 | Notch1 regulates the fate of cardiac progenitor cells. *Proceedings of the National Academy of Sciences of the United States of America*, **2008**, 105, 15529-34 | 11.5 | 169 |
| 159 | Local activation or implantation of cardiac progenitor cells rescues scarred infarcted myocardium improving cardiac function. *Circulation Research*, **2008**, 103, 107-16 | 15.7 | 236 |
| 158 | Impact of 6-mo caloric restriction on myocardial ischemic tolerance: possible involvement of nitric oxide-dependent increase in nuclear Sirt1. *American Journal of Physiology - Heart and Circulatory Physiology*, **2008**, 295, H2348-55 | 5.2 | 109 |
| 157 | Loss of ischaemic preconditioning in ovariectomized rat hearts: possible involvement of impaired protein kinase C epsilon phosphorylation. *Cardiovascular Research*, **2008**, 79, 387-94 | 9.9 | 29 |
| 156 | Formation of large coronary arteries by cardiac progenitor cells. *Proceedings of the National Academy of Sciences of the United States of America*, **2008**, 105, 1668-73 | 11.5 | 142 |
| 155 | Cardiac myocyte-specific expression of inducible nitric oxide synthase protects against ischemia/reperfusion injury by preventing mitochondrial permeability transition. *Circulation*, **2008**, 118, 1970-8 | 16.7 | 101 |
| 154 | Transplantation of bone marrow-derived very small embryonic-like stem cells attenuates left ventricular dysfunction and remodeling after myocardial infarction. *Stem Cells*, **2008**, 26, 1646-55 | 5.8 | 120 |
| 153 | Cardioprotection in iNOS transgenic mice is independent of mitochondrial biogenesis.. *FASEB Journal*, **2008**, 22, 835.2 | 0.9 | |
| 152 | Preconditioning: a paradigm shift in the biology of myocardial ischemia. *American Journal of Physiology - Heart and Circulatory Physiology*, **2007**, 292, H19-27 | 5.2 | 152 |

| | | | |
|---|---|---|---|
| 151 | Pretreatment with intracoronary enalaprilat protects human myocardium during percutaneous coronary angioplasty. *Journal of the American College of Cardiology*, **2007**, 49, 1607-1610 | 15.1 | 18 |
| 150 | The late phase of preconditioning and its natural clinical application--gene therapy. *Heart Failure Reviews*, **2007**, 12, 189-99 | 5 | 57 |
| 149 | Effects of anesthesia on echocardiographic assessment of left ventricular structure and function in rats. *Basic Research in Cardiology*, **2007**, 102, 28-41 | 11.8 | 99 |
| 148 | The cardioprotection of the late phase of ischemic preconditioning is enhanced by postconditioning via a COX-2-mediated mechanism in conscious rats. *American Journal of Physiology - Heart and Circulatory Physiology*, **2007**, 293, H2557-64 | 5.2 | 32 |
| 147 | Cardioprotection afforded by inducible nitric oxide synthase gene therapy is mediated by cyclooxygenase-2 via a nuclear factor-kappaB dependent pathway. *Circulation*, **2007**, 116, 1577-84 | 16.7 | 51 |
| 146 | CRYAB and HSPB2 deficiency alters cardiac metabolism and paradoxically confers protection against myocardial ischemia in aging mice. *American Journal of Physiology - Heart and Circulatory Physiology*, **2007**, 293, H3201-9 | 5.2 | 36 |
| 145 | Endothelial nitric oxide synthase plays an obligatory role in the late phase of ischemic preconditioning by activating the protein kinase C epsilon p44/42 mitogen-activated protein kinase pSer-signal transducers and activators of transcription1/3 pathway. *Circulation*, **2007**, 116, 535-44 | 16.7 | 70 |
| 144 | Bone marrow for cardiac repair: the importance of characterizing the phenotype and function of injected cells. *European Heart Journal*, **2007**, 28, 651-2 | 9.5 | 18 |
| 143 | Adult bone marrow-derived cells for cardiac repair: a systematic review and meta-analysis. *Archives of Internal Medicine*, **2007**, 167, 989-97 | | 710 |
| 142 | The late phase of ischemic preconditioning induces a prosurvival genetic program that results in marked attenuation of apoptosis. *Journal of Molecular and Cellular Cardiology*, **2007**, 42, 1075-85 | 5.8 | 22 |
| 141 | Human cardiac stem cells. *Proceedings of the National Academy of Sciences of the United States of America*, **2007**, 104, 14068-73 | 11.5 | 827 |
| 140 | An obligatory role of STAT1 in the upregulation of cardioprotective proteins and delayed cardioprotection in ischemic preconditioning. *FASEB Journal*, **2007**, 21, A1376 | 0.9 | |
| 139 | An In Vivo Evidence That Murine Very Small Embryonic Like (VSEL) Stem Cells Are Mobilized into Peripheral Blood after Acute Myocardial Infarction (AMI) and Contribute to Myocardiac Regeneration.. *Blood*, **2007**, 110, 3694-3694 | 2.2 | |
| 138 | Gene therapy with iNOS provides long-term protection against myocardial infarction without adverse functional consequences. *American Journal of Physiology - Heart and Circulatory Physiology*, **2006**, 290, H584-9 | 5.2 | 41 |
| 137 | Cardioprotection by postconditioning in conscious rats is limited to coronary occlusions . *American Journal of Physiology - Heart and Circulatory Physiology*, **2006**, 291, H2308-17 | 5.2 | 54 |
| 136 | Life and death of cardiac stem cells: a paradigm shift in cardiac biology. *Circulation*, **2006**, 113, 1451-63 | 16.7 | 319 |
| 135 | Stem cell niches in the adult mouse heart. *Proceedings of the National Academy of Sciences of the United States of America*, **2006**, 103, 9226-31 | 11.5 | 386 |
| 134 | Postinfarct cytokine therapy regenerates cardiac tissue and improves left ventricular function. *Circulation Research*, **2006**, 98, 1098-105 | 15.7 | 79 |

| | | | |
|---|---|---|---|
| 133 | Increasing evidence that estrogen is an important modulator of bone marrow-mediated cardiac repair after acute infarction. *Circulation*, **2006**, 114, 2203-5 | 16.7 | 9 |
| 132 | The ubiquitous role of nitric oxide in cardioprotection. *Journal of Molecular and Cellular Cardiology*, **2006**, 40, 16-23 | 5.8 | 356 |
| 131 | Administration of a CO-releasing molecule induces late preconditioning against myocardial infarction. *Journal of Molecular and Cellular Cardiology*, **2005**, 38, 127-34 | 5.8 | 114 |
| 130 | Adult bone marrow-derived cells: regenerative potential, plasticity, and tissue commitment. *Basic Research in Cardiology*, **2005**, 100, 494-503 | 11.8 | 96 |
| 129 | Cardiac preconditioning during percutaneous coronary interventions. *Cardiovascular Drugs and Therapy*, **2005**, 19, 211-7 | 3.9 | 10 |
| 128 | Prostacyclin attenuates oxidative damage of myocytes by opening mitochondrial ATP-sensitive K+ channels via the EP3 receptor. *American Journal of Physiology - Heart and Circulatory Physiology*, **2005**, 288, H2093-101 | 5.2 | 46 |
| 127 | Late preconditioning induced by NO donors, adenosine A1 receptor agonists, and delta1-opioid receptor agonists is mediated by iNOS. *American Journal of Physiology - Heart and Circulatory Physiology*, **2005**, 289, H2251-7 | 5.2 | 44 |
| 126 | No pain, no gain: the useful function of angina. *Circulation*, **2005**, 112, 3541-3 | 16.7 | 16 |
| 125 | Hypercholesterolemia abrogates late preconditioning via a tetrahydrobiopterin-dependent mechanism in conscious rabbits. *Circulation*, **2005**, 112, 2149-56 | 16.7 | 42 |
| 124 | Delayed preconditioning-mimetic actions of nitroglycerin in patients undergoing exercise tolerance tests. *Circulation*, **2005**, 111, 2565-71 | 16.7 | 44 |
| 123 | Role of the protein kinase C-epsilon-Raf-1-MEK-1/2-p44/42 MAPK signaling cascade in the activation of signal transducers and activators of transcription 1 and 3 and induction of cyclooxygenase-2 after ischemic preconditioning. *Circulation*, **2005**, 112, 1971-8 | 16.7 | 118 |
| 122 | Cardiac stem cells delivered intravascularly traverse the vessel barrier, regenerate infarcted myocardium, and improve cardiac function. *Proceedings of the National Academy of Sciences of the United States of America*, **2005**, 102, 3766-71 | 11.5 | 411 |
| 121 | The risk for myocardial infarction with cyclooxygenase-2 inhibitors. *Annals of Internal Medicine*, **2005**, 143, 617; author reply 617-8 | 8 | 3 |
| 120 | Cardioprotection during the final stage of the late phase of ischemic preconditioning is mediated by neuronal NO synthase in concert with cyclooxygenase-2. *Circulation Research*, **2004**, 95, 84-91 | 15.7 | 50 |
| 119 | IL-6 plays an obligatory role in late preconditioning via JAK-STAT signaling and upregulation of iNOS and COX-2. *Cardiovascular Research*, **2004**, 64, 61-71 | 9.9 | 156 |
| 118 | Cells expressing early cardiac markers reside in the bone marrow and are mobilized into the peripheral blood after myocardial infarction. *Circulation Research*, **2004**, 95, 1191-9 | 15.7 | 287 |
| 117 | Nicorandil induces late preconditioning against myocardial infarction in conscious rabbits. *American Journal of Physiology - Heart and Circulatory Physiology*, **2004**, 286, H1273-80 | 5.2 | 18 |
| 116 | Delayed adaptation of the heart to stress: late preconditioning. *Stroke*, **2004**, 35, 2676-9 | 6.7 | 90 |

| | | | |
|---|---|---|---|
| 115 | Administration of a CO-releasing molecule at the time of reperfusion reduces infarct size in vivo. *American Journal of Physiology - Heart and Circulatory Physiology*, **2004**, 286, H1649-53 | 5.2 | 175 |
| 114 | Gender and aging do not impair opioid-induced late preconditioning in rats. *Basic Research in Cardiology*, **2004**, 99, 46-55 | 11.8 | 29 |
| 113 | Hypercholesterolemia blunts NO donor-induced late preconditioning against myocardial infarction in conscious rabbits. *Basic Research in Cardiology*, **2004**, 99, 395-403 | 11.8 | 20 |
| 112 | Myocardial protection at a crossroads: the need for translation into clinical therapy. *Circulation Research*, **2004**, 95, 125-34 | 15.7 | 357 |
| 111 | Tumor necrosis factor-alpha does not modulate ischemia/reperfusion injury in naïve myocardium but is essential for the development of late preconditioning. *Journal of Molecular and Cellular Cardiology*, **2004**, 37, 51-61 | 5.8 | 59 |
| 110 | CXCR4+ CD45− Tissue-Committed Stem Cells (TCSC) for Myocardium Reside in the Bone Marrow, Are Mobilized into the Peripheral Blood during Myocardial Infarction, and "Home" to Infarcted Myocardium in CXCR4-SDF-1 and HGF/SF-c-Met Dependent Manner.. *Blood*, **2004**, 104, 2131-2131 | 2.2 | |
| 109 | Protein tyrosine kinase signaling is necessary for NO donor-induced late preconditioning against myocardial stunning. *American Journal of Physiology - Heart and Circulatory Physiology*, **2003**, 284, H1441-8 | 5.2 | 11 |
| 108 | Cardioprotection involves activation of NF-kappa B via PKC-dependent tyrosine and serine phosphorylation of I kappa B-alpha. *American Journal of Physiology - Heart and Circulatory Physiology*, **2003**, 285, H1753-8 | 5.2 | 22 |
| 107 | Role of the JAK-STAT pathway in protection against myocardial ischemia/reperfusion injury. *Trends in Cardiovascular Medicine*, **2003**, 13, 72-9 | 6.9 | 155 |
| 106 | The role of sodium-hydrogen ion exchange in patients undergoing coronary artery bypass grafting. *Journal of Cardiac Surgery*, **2003**, 18 Suppl 1, 21-6 | 1.3 | 7 |
| 105 | Cyclooxygenase-2 in myocardial ischemia: is it really a friend? Reply. *Journal of the American College of Cardiology*, **2003**, 42, 1714-1715 | 15.1 | |
| 104 | Effect of aspirin on late preconditioning against myocardial stunning in conscious rabbits. *Journal of the American College of Cardiology*, **2003**, 41, 1183-94 | 15.1 | 32 |
| 103 | Nonelectrocardiographic evidence that both ischemic preconditioning and adenosine preconditioning exist in humans. *Journal of the American College of Cardiology*, **2003**, 42, 437-45 | 15.1 | 33 |
| 102 | Mechanism of cyclooxygenase-2 upregulation in late preconditioning. *Journal of Molecular and Cellular Cardiology*, **2003**, 35, 525-37 | 5.8 | 85 |
| 101 | Gene therapy with inducible nitric oxide synthase protects against myocardial infarction via a cyclooxygenase-2-dependent mechanism. *Circulation Research*, **2003**, 92, 741-8 | 15.7 | 69 |
| 100 | COX-2-derived prostacyclin mediates opioid-induced late phase of preconditioning in isolated rat hearts. *American Journal of Physiology - Heart and Circulatory Physiology*, **2002**, 283, H2534-43 | 5.2 | 39 |
| 99 | Role of Src protein tyrosine kinases in late preconditioning against myocardial infarction. *American Journal of Physiology - Heart and Circulatory Physiology*, **2002**, 283, H549-56 | 5.2 | 13 |
| 98 | Oxidant species trigger late preconditioning against myocardial stunning in conscious rabbits. *American Journal of Physiology - Heart and Circulatory Physiology*, **2002**, 282, H281-91 | 5.2 | 43 |

| | | | |
|---|---|---|---|
| 97 | Role of nitric oxide in myocardial preconditioning. *Annals of the New York Academy of Sciences*, **2002**, 962, 18-41 | 6.5 | 147 |
| 96 | Role of cyclic guanosine monophosphate in late preconditioning in conscious rabbits. *Circulation*, **2002**, 105, 3046-52 | 16.7 | 36 |
| 95 | Gene dosage-dependent effects of cardiac-specific overexpression of the A3 adenosine receptor. *Circulation Research*, **2002**, 91, 165-72 | 15.7 | 75 |
| 94 | Discovery of a new function of cyclooxygenase (COX)-2: COX-2 is a cardioprotective protein that alleviates ischemia/reperfusion injury and mediates the late phase of preconditioning. *Cardiovascular Research*, **2002**, 55, 506-19 | 9.9 | 189 |
| 93 | Aldose reductase is an obligatory mediator of the late phase of ischemic preconditioning. *Circulation Research*, **2002**, 91, 240-6 | 15.7 | 109 |
| 92 | Inducible nitric oxide synthase modulates cyclooxygenase-2 activity in the heart of conscious rabbits during the late phase of ischemic preconditioning. *Circulation Research*, **2002**, 90, 602-8 | 15.7 | 137 |
| 91 | Ischemic preconditioning upregulates inducible nitric oxide synthase in cardiac myocyte. *Journal of Molecular and Cellular Cardiology*, **2002**, 34, 5-15 | 5.8 | 80 |
| 90 | Formation of protein kinase C□Lck signaling modules confers cardioprotection. *Journal of Clinical Investigation*, **2002**, 109, 499-507 | 15.9 | 97 |
| 89 | Formation of protein kinase C(epsilon)-Lck signaling modules confers cardioprotection. *Journal of Clinical Investigation*, **2002**, 109, 499-507 | 15.9 | 48 |
| 88 | Gene therapy with extracellular superoxide dismutase protects conscious rabbits against myocardial infarction. *Circulation*, **2001**, 103, 1893-8 | 16.7 | 120 |
| 87 | Protection of IB-MECA against myocardial stunning in conscious rabbits is not mediated by the A1 adenosine receptor. *Basic Research in Cardiology*, **2001**, 96, 487-96 | 11.8 | 16 |
| 86 | Delayed preconditioning-mimetic action of nitroglycerin in patients undergoing coronary angioplasty. *Circulation*, **2001**, 103, 2935-41 | 16.7 | 148 |
| 85 | Nitroglycerin induces late preconditioning against myocardial infarction in conscious rabbits despite development of nitrate tolerance. *Circulation*, **2001**, 104, 694-9 | 16.7 | 84 |
| 84 | Protein kinase C epsilon-Src modules direct signal transduction in nitric oxide-induced cardioprotection: complex formation as a means for cardioprotective signaling. *Circulation Research* , **2001**, 88, 1306-13 | 15.7 | 94 |
| 83 | A(1) or A(3) adenosine receptors induce late preconditioning against infarction in conscious rabbits by different mechanisms. *Circulation Research*, **2001**, 88, 520-8 | 15.7 | 117 |
| 82 | Cardiac-specific abrogation of NF- kappa B activation in mice by transdominant expression of a mutant I kappa B alpha. *Journal of Molecular and Cellular Cardiology*, **2001**, 33, 161-73 | 5.8 | 50 |
| 81 | Targeted deletion of the A3 adenosine receptor confers resistance to myocardial ischemic injury and does not prevent early preconditioning. *Journal of Molecular and Cellular Cardiology*, **2001**, 33, 825-30 | 5.8 | 67 |
| 80 | Cardioprotective function of inducible nitric oxide synthase and role of nitric oxide in myocardial ischemia and preconditioning: an overview of a decade of research. *Journal of Molecular and Cellular Cardiology*, **2001**, 33, 1897-918 | 5.8 | 495 |

| | | | |
|---|---|---|---|
| 79 | Toward a better understanding of the metabolic effects of ischemic preconditioning in humans. *Journal of Cardiothoracic and Vascular Anesthesia*, **2001**, 15, 409-11 | 2.1 | 8 |
| 78 | Exercise-induced late preconditioning is triggered by generation of nitric oxide. *Journal of Molecular and Cellular Cardiology*, **2001**, 33, A41 | 5.8 | 5 |
| 77 | Enhanced PKC beta II translocation and PKC beta II-RACK1 interactions in PKC epsilon-induced heart failure: a role for RACK1. *American Journal of Physiology - Heart and Circulatory Physiology*, **2001**, 281, H2500-10 | 5.2 | 56 |
| 76 | Cyclooxygenase-2 does not mediate late preconditioning induced by activation of adenosine A1 or A3 receptors. *American Journal of Physiology - Heart and Circulatory Physiology*, **2001**, 281, H959-68 | 5.2 | 26 |
| 75 | PKCepsilon activation induces dichotomous cardiac phenotypes and modulates PKCepsilon-RACK interactions and RACK expression. *American Journal of Physiology - Heart and Circulatory Physiology*, **2001**, 280, H946-55 | 5.2 | 70 |
| 74 | Evidence for an essential role of cyclooxygenase-2 as a mediator of the late phase of ischemic preconditioning in mice. *Basic Research in Cardiology*, **2000**, 95, 479-84 | 11.8 | 83 |
| 73 | PKCepsilon modulates NF-kappaB and AP-1 via mitogen-activated protein kinases in adult rabbit cardiomyocytes. *American Journal of Physiology - Heart and Circulatory Physiology*, **2000**, 279, H1679-89 | 5.2 | 91 |
| 72 | Differential role of K(ATP) channels in late preconditioning against myocardial stunning and infarction in rabbits. *American Journal of Physiology - Heart and Circulatory Physiology*, **2000**, 279, H2350-9 | 5.2 | 42 |
| 71 | Biphasic response of cardiac NO synthase isoforms to ischemic preconditioning in conscious rabbits. *American Journal of Physiology - Heart and Circulatory Physiology*, **2000**, 279, H2360-71 | 5.2 | 104 |
| 70 | Late preconditioning enhances recovery of myocardial function after infarction in conscious rabbits. *American Journal of Physiology - Heart and Circulatory Physiology*, **2000**, 279, H2372-81 | 5.2 | 8 |
| 69 | Transgenic overexpression of constitutively active protein kinase C epsilon causes concentric cardiac hypertrophy. *Circulation Research*, **2000**, 86, 1218-23 | 15.7 | 229 |
| 68 | Functional Proteomic Analysis of Protein Kinase C ε Signaling Complexes in Preconditioning.. *Circulation*, **2000**, 102, 2672-2672 | 16.7 | 1 |
| 67 | The late phase of preconditioning. *Circulation Research*, **2000**, 87, 972-83 | 15.7 | 607 |
| 66 | Molecular and cellular mechanisms of myocardial stunning. *Physiological Reviews*, **1999**, 79, 609-34 | 47.9 | 841 |
| 65 | PKC-dependent activation of p44/p42 MAPKs during myocardial ischemia-reperfusion in conscious rabbits. *American Journal of Physiology - Heart and Circulatory Physiology*, **1999**, 276, H1468-81 | 5.2 | 90 |
| 64 | Nitroglycerin induces late preconditioning against myocardial stunning via a PKC-dependent pathway. *American Journal of Physiology - Heart and Circulatory Physiology*, **1999**, 277, H2488-94 | 5.2 | 33 |
| 63 | PKC-dependent activation of p46/p54 JNKs during ischemic preconditioning in conscious rabbits. *American Journal of Physiology - Heart and Circulatory Physiology*, **1999**, 277, H1771-85 | 5.2 | 47 |
| 62 | Bifunctional role of protein tyrosine kinases in late preconditioning against myocardial stunning in conscious rabbits. *Circulation Research*, **1999**, 85, 1154-63 | 15.7 | 39 |

| | | | |
|---|---|---|---|
| 61 | Isoform-selective activation of protein kinase C by nitric oxide in the heart of conscious rabbits: a signaling mechanism for both nitric oxide-induced and ischemia-induced preconditioning. *Circulation Research*, **1999**, 84, 587-604 | 15.7 | 235 |
| 60 | Nuclear factor-kappaB plays an essential role in the late phase of ischemic preconditioning in conscious rabbits. *Circulation Research*, **1999**, 84, 1095-109 | 15.7 | 273 |
| 59 | Demonstration of selective protein kinase C-dependent activation of Src and Lck tyrosine kinases during ischemic preconditioning in conscious rabbits. *Circulation Research*, **1999**, 85, 542-50 | 15.7 | 145 |
| 58 | Bradykinin-induced preconditioning in patients undergoing coronary angioplasty. *Journal of the American College of Cardiology*, **1999**, 34, 639-50 | 15.1 | 109 |
| 57 | Ischemic preconditioning increases iNOS transcript levels in conscious rabbits via a nitric oxide-dependent mechanism. *Journal of Molecular and Cellular Cardiology*, **1999**, 31, 1469-81 | 5.8 | 68 |
| 56 | Basic and clinical aspects of myocardial stunning. *Progress in Cardiovascular Diseases*, **1998**, 40, 477-516 | 8.5 | 89 |
| 55 | Gene therapy with extracellular superoxide dismutase attenuates myocardial stunning in conscious rabbits. *Circulation*, **1998**, 98, 1438-48 | 16.7 | 86 |
| 54 | Nitric oxide synthase is the mediator of late preconditioning against myocardial infarction in conscious rabbits. *Circulation*, **1998**, 98, 441-9 | 16.7 | 219 |
| 53 | Nitric oxide donors induce late preconditioning against myocardial stunning and infarction in conscious rabbits via an antioxidant-sensitive mechanism. *Circulation Research*, **1998**, 83, 73-84 | 15.7 | 210 |
| 52 | Demonstration of an early and a late phase of ischemic preconditioning in mice. *American Journal of Physiology - Heart and Circulatory Physiology*, **1998**, 275, H1375-87 | 5.2 | 118 |
| 51 | Nitric oxide triggers late preconditioning against myocardial infarction in conscious rabbits. *American Journal of Physiology - Heart and Circulatory Physiology*, **1997**, 273, H2931-6 | 5.2 | 50 |
| 50 | Does Lethal Myocardial Reperfusion Injury Exist? A Controversy that is Unlikely to Be Settled in our Lifetime. *Journal of Thrombosis and Thrombolysis*, **1997**, 4, 109-110 | 5.1 | 1 |
| 49 | Preconditioning of human myocardium with adenosine during coronary angioplasty. *Circulation*, **1997**, 95, 2500-7 | 16.7 | 171 |
| 48 | The early and late phases of ischemic preconditioning: a comparative analysis of their effects on infarct size, myocardial stunning, and arrhythmias in conscious pigs undergoing a 40-minute coronary occlusion. *Circulation Research*, **1997**, 80, 730-42 | 15.7 | 52 |
| 47 | Selective activation of A3 adenosine receptors with N6-(3-iodobenzyl)adenosine-5'-N-methyluronamide protects against myocardial stunning and infarction without hemodynamic changes in conscious rabbits. *Circulation Research*, **1997**, 80, 800-9 | 15.7 | 127 |
| 46 | Evidence that late preconditioning against myocardial stunning in conscious rabbits is triggered by the generation of nitric oxide. *Circulation Research*, **1997**, 81, 42-52 | 15.7 | 178 |
| 45 | Ischemic preconditioning induces selective translocation of protein kinase C isoforms epsilon and eta in the heart of conscious rabbits without subcellular redistribution of total protein kinase C activity. *Circulation Research*, **1997**, 81, 404-14 | 15.7 | 346 |
| 44 | The protective effect of late preconditioning against myocardial stunning in conscious rabbits is mediated by nitric oxide synthase. Evidence that nitric oxide acts both as a trigger and as a mediator of the late phase of ischemic preconditioning. *Circulation Research*, **1997**, 81, 1094-107 | 15.7 | 224 |

| | | | |
|---|---|---|---|
| 43 | Time course of late preconditioning against myocardial stunning in conscious pigs. *Circulation Research*, **1996**, 79, 424-34 | 15.7 | 80 |
| 42 | An accurate, nontraumatic ultrasonic method to monitor myocardial wall thickening in patients undergoing cardiac surgery. *Journal of the American College of Cardiology*, **1990**, 15, 1055-65 | 15.1 | 33 |
| 41 | Activation of the complement system by recombinant tissue plasminogen activator. *Journal of the American College of Cardiology*, **1987**, 10, 627-32 | 15.1 | 94 |
| 40 | Pharmacological Models of Hypertrophy and Failure170-176 | | |
| 39 | Confocal Imaging of Intracellular Calcium Cycling in Isolated Cardiac Myocytes12-19 | | |
| 38 | Quantification and Characterization of Atherosclerotic Lesions in Mice320-331 | | |
| 37 | Coronary Ligation155-163 | | |
| 36 | Murine Bone Marrow Transplantation Model146-148 | | |
| 35 | Generation of Cre-loxPMouse Models for Conditional Knockout and Overexpression of Genes in Various Heart Cells387-396 | | |
| 34 | The Setting: Imaging Conscious, Sedated, or Anesthetized rodents250-253 | | |
| 33 | Cardiac Resident Stem Cells87-94 | | |
| 32 | Mesenchymal Stem Cells104-109 | | |
| 31 | Modulation of Myocardial Genes via Use of Adenoviral Vectors and RNA Interference Approaches397-406 | | |
| 30 | Fractionation of Cardiomyocytes and Isolation of Mitochondria305-312 | | |
| 29 | Vascular and Cardiac Studies in Drosophila432-439 | | |
| 28 | Assessment of Mitochondrial Function in Isolated Cells343-350 | | |
| 27 | In Vivo microRNA Studies416-422 | | |
| 26 | Measurement of Calcium Transient ex vivo1-11 | | |

| | | |
|---|---|---|
| 7 | Measurement of Reactive Oxygen Species in Cardiovascular Disease359-370 | |
| 6 | Vascular and Cardiac Studies in Zebrafish423-431 | |
| 5 | The Langendorff Preparation187-196 | 1 |
| 4 | Myocarditis and Other Immunological Models of Cardiac Disease197-202 | 1 |
| 3 | Assessment of Cell Death in the Heart332-342 | 1 |
| 2 | Assessment of Cardiomyocyte Size378-385 | 2 |
| 1 | Recording and Measurement of Action Potentials41-49 | 1 |